ofloxacin

Summary

Summary: A synthetic fluoroquinolone (FLUOROQUINOLONES) antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.

Top Publications

  1. pmc Killing by ampicillin and ofloxacin induces overlapping changes in Escherichia coli transcription profile
    Niilo Kaldalu
    Department of Biology, Northeastern University, Boston, Massachusetts 02115, USA
    Antimicrob Agents Chemother 48:890-6. 2004
  2. pmc The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapy
    Christopher M Parry
    Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
    PLoS Negl Trop Dis 5:e1163. 2011
  3. ncbi A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis
    R Rustomjee
    Unit for Clinical and Biomedical TB Research, Medical Research Council, Durban, South Africa
    Int J Tuberc Lung Dis 12:128-38. 2008
  4. pmc Suitable disk antimicrobial susceptibility breakpoints defining Salmonella enterica serovar Typhi isolates with reduced susceptibility to fluoroquinolones
    Christopher M Parry
    The Hospital for Tropical Diseases, Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, 190 Ben Ham Tu, Quan 5, Ho Chi Minh City, Vietnam
    Antimicrob Agents Chemother 54:5201-8. 2010
  5. pmc Starvation, together with the SOS response, mediates high biofilm-specific tolerance to the fluoroquinolone ofloxacin
    Steve P Bernier
    Institut Pasteur, Unité de Génétique des Biofilms, Paris, France
    PLoS Genet 9:e1003144. 2013
  6. ncbi Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy
    Laarni G Villahermosa
    Leonard Wood Memorial Center for Leprosy Research, Cebu, The Philippines
    Am J Trop Med Hyg 70:197-200. 2004
  7. ncbi Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients
    Jung Mogg Kim
    Department of Microbiology and Institute of Biomedical Science, Hanyang University College of Medicine, Seoul, Korea
    J Antimicrob Chemother 56:965-7. 2005
  8. ncbi Long term follow-up results of 1 year MDT in MB leprosy patients treated with standard MDT + once a month Minocycline and Ofloxacin
    K Katoch
    Medical Unit I, National JALMA Institute for Leprosy and Other Mycobacterial Diseases ICMR, Department of Health Research, Ministry of Health and Family Welfare, Government of India, Dr M Miyazaki Marg, Tajganj, Agra 282001, India
    Indian J Lepr 80:331-44. 2008
  9. pmc Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex
    S Y Grace Lin
    Microbial Diseases Laboratory, CDPH, 850 Marina Bay Parkway, Richmond, CA 94804, USA
    J Clin Microbiol 47:3630-4. 2009
  10. pmc Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing
    Ruiru Shi
    Mycobacterial Reference Center, The Research Institute of Tuberculosis, 3 1 24 Matsuyama, Kiyose, Tokyo 204 0022, Japan
    J Clin Microbiol 44:4566-8. 2006

Detail Information

Publications307 found, 100 shown here

  1. pmc Killing by ampicillin and ofloxacin induces overlapping changes in Escherichia coli transcription profile
    Niilo Kaldalu
    Department of Biology, Northeastern University, Boston, Massachusetts 02115, USA
    Antimicrob Agents Chemother 48:890-6. 2004
    ..log-phase Escherichia coli treated with bactericidal concentrations of two unrelated antibiotics: ampicillin and ofloxacin. Massive changes in transcription profile were observed in response to either agent, and there was a significant ..
  2. pmc The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapy
    Christopher M Parry
    Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, The Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam
    PLoS Negl Trop Dis 5:e1163. 2011
    ..We studied the relationship between ofloxacin treatment response and the ofloxacin minimum inhibitory concentration (MIC) of the infecting isolate...
  3. ncbi A Phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis
    R Rustomjee
    Unit for Clinical and Biomedical TB Research, Medical Research Council, Durban, South Africa
    Int J Tuberc Lung Dis 12:128-38. 2008
    ..Current treatment for pulmonary tuberculosis (TB) might be shortened by the incorporation of fluoroquinolones (FQs)...
  4. pmc Suitable disk antimicrobial susceptibility breakpoints defining Salmonella enterica serovar Typhi isolates with reduced susceptibility to fluoroquinolones
    Christopher M Parry
    The Hospital for Tropical Diseases, Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit, 190 Ben Ham Tu, Quan 5, Ho Chi Minh City, Vietnam
    Antimicrob Agents Chemother 54:5201-8. 2010
    Infections with Salmonella enterica serovar Typhi isolates that have reduced susceptibility to ofloxacin (MIC ≥ 0.25 μg/ml) or ciprofloxacin (MIC ≥ 0...
  5. pmc Starvation, together with the SOS response, mediates high biofilm-specific tolerance to the fluoroquinolone ofloxacin
    Steve P Bernier
    Institut Pasteur, Unité de Génétique des Biofilms, Paris, France
    PLoS Genet 9:e1003144. 2013
    ..acid auxotroph mutants, that starved biofilms exhibited significantly greater tolerance towards fluoroquinolone ofloxacin than their planktonic counterparts...
  6. ncbi Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy
    Laarni G Villahermosa
    Leonard Wood Memorial Center for Leprosy Research, Cebu, The Philippines
    Am J Trop Med Hyg 70:197-200. 2004
    Monthly doses of rifampin, ofloxacin, and minocycline (ROM) are expected to be effective treatment for multi-bacillary leprosy. Patients with MB leprosy received ROM (n = 10) or World Health Organization multi-drug therapy (MDT) (n = 11)...
  7. ncbi Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients
    Jung Mogg Kim
    Department of Microbiology and Institute of Biomedical Science, Hanyang University College of Medicine, Seoul, Korea
    J Antimicrob Chemother 56:965-7. 2005
    ..The aim of this study was to assess the prevalence rate of primary fluoroquinolone resistance in Helicobacter pylori isolates from Korean patients over the past 16 years...
  8. ncbi Long term follow-up results of 1 year MDT in MB leprosy patients treated with standard MDT + once a month Minocycline and Ofloxacin
    K Katoch
    Medical Unit I, National JALMA Institute for Leprosy and Other Mycobacterial Diseases ICMR, Department of Health Research, Ministry of Health and Family Welfare, Government of India, Dr M Miyazaki Marg, Tajganj, Agra 282001, India
    Indian J Lepr 80:331-44. 2008
    ..It was also envisaged to see if the addition of newer bactericidal drugs would be beneficial...
  9. pmc Multicenter evaluation of Bactec MGIT 960 system for second-line drug susceptibility testing of Mycobacterium tuberculosis complex
    S Y Grace Lin
    Microbial Diseases Laboratory, CDPH, 850 Marina Bay Parkway, Richmond, CA 94804, USA
    J Clin Microbiol 47:3630-4. 2009
    ..1% for levofloxacin, 100% for amikacin, 97.4% for capreomycin, and 88.9% for ethionamide. The rate of reproducibility of the drug susceptibility testing results between the participating laboratories was 99.5%...
  10. pmc Emergence of ofloxacin resistance in Mycobacterium tuberculosis clinical isolates from China as determined by gyrA mutation analysis using denaturing high-pressure liquid chromatography and DNA sequencing
    Ruiru Shi
    Mycobacterial Reference Center, The Research Institute of Tuberculosis, 3 1 24 Matsuyama, Kiyose, Tokyo 204 0022, Japan
    J Clin Microbiol 44:4566-8. 2006
    A high rate of double point mutations in gyrA (56% of 87 ofloxacin-resistant Mycobacterium tuberculosis clinical isolates) indicates the emergence of fluoroquinolone resistance...
  11. pmc Sequence analyses of just four genes to detect extensively drug-resistant Mycobacterium tuberculosis strains in multidrug-resistant tuberculosis patients undergoing treatment
    Silke Feuerriegel
    Research Center Borstel, National Reference Center for Mycobacteria, Parkallee 18, 23845 Borstel, Germany
    Antimicrob Agents Chemother 53:3353-6. 2009
    ..To address this question, we analyzed Mycobacterium tuberculosis strains resistant to ofloxacin (n = 26) and to capreomycin and/or amikacin (n = 48) from Uzbekistan for variations in target genes (gyrA, gyrB, ..
  12. pmc Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux
    Gail E Louw
    Department of Biomedical Sciences, Faculty of Health Sciences, Stellenbosch University, Cape Town, South Africa
    Am J Respir Crit Care Med 184:269-76. 2011
    ..Central dogma suggests that rifampicin resistance in Mycobacterium tuberculosis develops solely through rpoB gene mutations...
  13. pmc Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model
    Julien Poissy
    Laboratoire de Bacteriologie Hygiene, Faculte de Medecine, Pierre et Marie Curie Université Paris, 91 Boulevard de l Hopital, Paris Cedex 13, France
    Antimicrob Agents Chemother 54:4765-71. 2010
    ..tuberculosis, may be lower than its peak serum level for some ofloxacin-resistant strains of Mycobacterium tuberculosis...
  14. ncbi Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis
    Richard J Saad
    Department of Medicine, Division of Gastroenterology, University of Michigan Medical Center, 3912 Taubman Center, Ann Arbor, MI 48109, USA
    Am J Gastroenterol 101:488-96. 2006
    ..Levofloxacin-based triple therapy has been suggested as an alternative salvage therapy to bismuth-based quadruple therapy for persistent Helicobacter pylori (H. pylori) infection...
  15. ncbi In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis
    J C Rodriguez
    Section of Microbiology, Hospital General Universitario de Elche, Universidad Miguel Hernandez, 03202 Elche, Alicante, Spain
    Int J Antimicrob Agents 20:464-7. 2002
    ..These new compounds may prove to be therapeutic alternatives for treatment of multi-resistant tuberculosis and further studies should be done to demonstrate their true usefulness...
  16. pmc Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB
    Andrea von Groll
    Mycobacteriology Unit, Institute of Tropical Medicine, Antwerp, Belgium
    Antimicrob Agents Chemother 53:4498-500. 2009
    This study evaluated cross-resistance of Mycobacterium tuberculosis strains to ofloxacin, moxifloxacin, and gatifloxacin and investigated the presence of mutations in gyrA and gyrB...
  17. pmc Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy
    O Lomovskaya
    Microcide Pharmaceuticals, Inc, Mountain View, California 94043, USA
    Antimicrob Agents Chemother 45:105-16. 2001
    ..aeruginosa strains that are highly resistant to fluoroquinolones...
  18. ncbi Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: ciclosporin, tacrolimus and levofloxacin in renal transplantation
    Stefano Federico
    Department of Systematic Pathology, Section of Renal Transplantation, Faculty of Medicine and Surgery, Federico II University of Naples, Naples, Italy
    Clin Pharmacokinet 45:169-75. 2006
    ..This study was performed to establish whether levofloxacin, a more recent fluoroquinolone that undergoes limited hepatic metabolism, interferes with metabolism and excretion of either ciclosporin microemulsion or tacrolimus...
  19. pmc Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterat
    S Brisse
    Eijkman Winkler Institute, Utrecht University, 3584 CX, Utrecht, The Netherlands
    Antimicrob Agents Chemother 43:2051-5. 1999
    ..Irrespective of the alterations in GyrA and ParC proteins, clinafloxacin exhibited greater activity than all other fluoroquinolones tested against K. pneumoniae and E. aerogenes...
  20. ncbi Ofloxacin induces oxidative damage to joint chondrocytes of juvenile rabbits: excessive production of reactive oxygen species, lipid peroxidation and DNA damage
    Qianqian Li
    Evaluation and Research Center for Toxicology, Institute of Disease Control and Prevention, Academy of Military Medical Sciences, 20 Dong Da Jie Street, Fengtai District, Beijing 100071, PR China
    Eur J Pharmacol 626:146-53. 2010
    ..This study was undertaken to investigate the role of oxidative damage in ofloxacin (one typical quinolones)-induced arthropathy...
  21. ncbi In vitro susceptibilities of bacterial ocular isolates to fluoroquinolones
    A Graves
    Santen, Inc, Napa, California 94558, USA
    Cornea 20:301-5. 2001
    To evaluate and compare the in vitro antimicrobial activity of levofloxacin versus ciprofloxacin and ofloxacin against ocular isolates from patients with bacterial conjunctivitis.
  22. ncbi Ofloxacin targeting to lungs by way of microspheres
    Sree Harsha
    Department of Pharmaceutics, College of Clinical Pharmacy, King Faisal University, Al Ahsa, Hufof, Saudi Arabia
    Int J Pharm 380:127-32. 2009
    ..As an application, lung-targeting albumin loaded ofloxacin microspheres (ALOME) were prepared by water in oil emulsion method...
  23. ncbi Activity of levofloxacin and ciprofloxacin against urinary pathogens
    L Drago
    Laboratory of Clinical Microbiology, Department of Preclinical Science, LITA Vialba, University of Milan, Via G B Grassi 74, 20157 Milano, Italy
    J Antimicrob Chemother 48:37-45. 2001
    ..125 x MIC. These findings suggest that levofloxacin is an effective alternative to ciprofloxacin in the treatment of urinary tract infections and that sub-inhibitory concentrations may contribute to efficacy...
  24. ncbi Levofloxacin 500 mg once daily versus cefuroxime 250 mg twice daily in patients with acute exacerbations of chronic obstructive bronchitis: clinical efficacy and exacerbation-free interval
    Patrick Petitpretz
    Hopital Andre Mignot, Le Chesnay, France
    Int J Antimicrob Agents 30:52-9. 2007
    ..In addition to demonstrating the non-inferiority of levofloxacin compared with cefuroxime in AECOB, the data from this study raise the question of whether EFI is a useful discriminative endpoint for comparing antimicrobial therapies...
  25. pmc Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates
    Sonia K Morgan-Linnell
    Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas 77030 3411, USA
    Antimicrob Agents Chemother 53:235-41. 2009
    ..Thus, additional, unknown fluoroquinolone resistance mechanisms must be present in some clinical isolates...
  26. ncbi Development of a spray-drying method for the formulation of respirable microparticles containing ofloxacin-palladium complex
    Francesco Palazzo
    Department of Chemistry and Technology of Drugs, Universita degli Studi di Perugia, Via del Liceo 1, 06123 Perugia, Italy
    Int J Pharm 440:273-82. 2013
    ..b>Ofloxacin (Ofx) was encapsulated as ofloxacin-palladium (Ofx-Pd) complex into poly DL-lactide (PLA) MP by spray-drying...
  27. ncbi gyrA mutations and phenotypic susceptibility levels to ofloxacin and moxifloxacin in clinical isolates of Mycobacterium tuberculosis
    Frederick A Sirgel
    DST NRF Centre of Excellence for Biomedical TB Research MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Faculty of Health Science, Stellenbosch University, Stellenbosch, South Africa
    J Antimicrob Chemother 67:1088-93. 2012
    To compare mutations in the quinolone resistance-determining region of the gyrA gene and flanking sequences with the MICs of ofloxacin and moxifloxacin for Mycobacterium tuberculosis.
  28. ncbi Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure
    J P Gisbert
    Department of Gastroenterology, University Hospital of La Princesa, Madrid, Spain
    Aliment Pharmacol Ther 23:35-44. 2006
    ..A quadruple therapy has been generally recommended as rescue regimen for Helicobacter pylori eradication failures...
  29. ncbi Characterisation of fluoroquinolone-resistant clinical isolates of Streptococcus pyogenes in Barcelona, Spain
    A Rivera
    Servei de Microbiologia, Hospital de la Santa Creu i Sant Pau, and Unitat de Microbiologia, Departament de Genetica i Microbiologia, Universitat Autonoma de Barcelona, Barcelona, Spain
    Clin Microbiol Infect 11:759-61. 2005
    ..27, and an additional substitution (Ser81-->Tyr) in GyrA. Resistance patterns, emm typing and sequencing of the quinolone resistance-determining regions defined two clusters containing three and two isolates, respectively...
  30. ncbi Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study
    P M Shah
    Klinikum der Johann Wolfgang Goethe Universitaet, Zentrum der Inneren Medizin, Medizinische Klinik III, Schwerpunkt Infektiologie, Frankfurt, Germany
    J Antimicrob Chemother 43:529-39. 1999
    ..All three treatment regimens were equally well tolerated. In conclusion, the results show that levofloxacin (250 mg and 500 mg) od is effective and well tolerated in the treatment of AECB in adult patients...
  31. ncbi Mutation characterization of gyrA and gyrB genes in levofloxacin-resistant Mycobacterium tuberculosis clinical isolates from Guangdong Province in China
    Xiaomao Yin
    Institute for Pulmonary Disease, Guangzhou Chest Hospital, Yuexiu District, Guangzhou City, Guangdong Province, China
    J Infect 61:150-4. 2010
    ..The aim of this study was to observe the molecular characterization of gyrA and gyrB genes in FQ-resistant MTB clinical isolates from Guangdong Province in China...
  32. ncbi Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones
    Syed Hamid Ali
    Department of Biological and Biomedical Sciences, The Aga Khan University, Karachi, Pakistan
    Antivir Ther 12:1-6. 2007
    ..Inhibition of gyrase activity by quinolones involves the interaction of these drugs with the helicase component of bacterial gyrase. DNA tumour viruses also encode helicases that are essential for their DNA replication in the host...
  33. ncbi Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results?
    A C Galles
    Laboratório ALERTA, Universidade Federal de Sao Paulo, Brazil
    J Chemother 20:38-42. 2008
    ..5% susceptible by published breakpoint criteria) and moxifloxacin (MIC(90), 2 micro g/ml) MIC results was observed indicating that moxifloxacin could be further evaluated as a therapeutic option for S. maltophilia infections...
  34. ncbi Characterization of pyrazinamide and ofloxacin resistance among drug resistant Mycobacterium tuberculosis isolates from Singapore
    Ann S G Lee
    Department of Clinical Research, Singapore General Hospital, Singapore
    Int J Infect Dis 6:48-51. 2002
    To evaluate rapid molecular approaches for the detection of pyrazinamide (PZA) and ofloxacin resistance, by screening 100 known drug-resistant Mycobacterium tuberculosis isolates.
  35. ncbi Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility
    Kai Man Kam
    Tuberculosis Reference Laboratory, Public Health Laboratory Centre, Centre for Health Protection, Department of Health, Hong Kong Special Administrative Region, 382 Nam Cheong Street, Shek Kip Mei, Kowloon, Hong Kong
    Microb Drug Resist 12:7-11. 2006
    ..multidrug-resistant (MDR) Mycobacterium tuberculosis (MTB), in vitro drug susceptibility tests on MOX and ofloxacin (OFX) using the MGIT system against 132 nonduplicate MDR MTB isolates (108 OFX-sensitive and 24 OFX-resistant) ..
  36. pmc Ofloxacin plus rifampicin versus doxycycline plus rifampicin in the treatment of brucellosis: a randomized clinical trial [ISRCTN11871179]
    Oguz Karabay
    Department of Infectious Disease and Clinical Microbiology, Abant Izzet Baysal University Izzet Baysal Medical Faculty Hospital, Bolu Turkey
    BMC Infect Dis 4:18. 2004
    ..The aim of the present study was to investigate the efficacy, adverse effects and cost of ofloxacin plus rifampicin therapy, and doxycycline plus rifampicin therapy and evaluate in the treatment of brucellosis.
  37. pmc Effect of efflux pump inhibitors on drug susceptibility of ofloxacin resistant Mycobacterium tuberculosis isolates
    Mradula Singh
    Department of Microbiology and Molecular Biology, National JALMA Institute for Leprosy and Other Mycobacterial Diseases ICMR, Agra, India
    Indian J Med Res 133:535-40. 2011
    ..tuberculosis...
  38. ncbi Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines
    K Sato
    Department of Microbiology, Shimane Medical University, Izumo, Shimane 693 8501, Japan
    J Antimicrob Chemother 52:199-203. 2003
    ..This implies that the cellular permeability of these quinolones is an important factor that determines their efficacy to eliminate intracellular MTB organisms...
  39. pmc Molecular characterization of ofloxacin-resistant Mycobacterium tuberculosis strains from Russia
    Igor Mokrousov
    Laboratory of Molecular Microbiology, St Petersburg Pasteur Institute, 197101 St Petersburg, Russia
    Antimicrob Agents Chemother 52:2937-9. 2008
    In this work, we studied the variation in the gyrA and gyrB genes in ofloxacin- and multidrug-resistant Mycobacterium tuberculosis strains circulating in northwest Russia...
  40. pmc Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults
    Keith A Rodvold
    College of Pharmacy, University of Illinois, Chicago, Illinois, USA
    Antimicrob Agents Chemother 47:2450-7. 2003
    ..Further studies are needed to determine the clinical significance of such high intrapulmonary concentrations in patients with respiratory tract infections...
  41. pmc Preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles
    ShuYu Xie
    Department of Preventive Veterinary Medicine, College of Veterinary Medicine, China Agricultural University, Beijing, People s Republic of China
    Int J Nanomedicine 6:547-55. 2011
    The purpose of this study was to use solid lipid nanoparticles (SLN) to improve the pharmacological activity of ofloxacin. Ofloxacin-loaded SLN were prepared using palmitic acid as lipid matrix and poly vinyl alcohol (PVA) as emulsifier ..
  42. ncbi In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis
    J C Rodriguez
    Section of Microbiology, Hospital General Universitario de Elche, Universidad Miguel Hernandez, 03202 Elche Alicante, Spain
    Int J Antimicrob Agents 17:229-31. 2001
    The in vitro activity of ciprofloxacin, ofloxacin, levofloxacin and moxifloxacin against strains of Mycobacterium tuberculosis was studied. Moxifloxacin and levofloxacin showed the greatest activity having an MIC(90) of 1 mg/l...
  43. pmc In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone
    Angela M Nilius
    Infectious Diseases Research, Abbott Laboratories, Abbott Park, Illinois 60064 3537, USA
    Antimicrob Agents Chemother 47:3260-9. 2003
    ....
  44. ncbi A comparative analysis of chromosomal aberrations in cultured human lymphocytes due to fluoroquinolone drugs at different expression periods
    M Anupama
    International Institute of Biotechnology and Toxicology, Padappai, Kancheepuram District, Tamil Nadu 601301, India
    Arch Toxicol 84:411-20. 2010
    ..to the analogous effects induced by some other second- and third-generation FQ antibacterial agents, namely ofloxacin (OFX), ciprofloxacin (CFX) and sparfloxacin (SFX)...
  45. ncbi Development of sustained release gastroretentive drug delivery system for ofloxacin: in vitro and in vivo evaluation
    Mahesh Chavanpatil
    Mumbai University Institute of Chemical Technology, Pharmaceutical Sciences Division, Near Nathalal Parikh Marg, Matunga, Mumbai 400019, India
    Int J Pharm 304:178-84. 2005
    ..A new strategy is proposed for the development of gastroretentive dosage forms for ofloxacin preferably once daily...
  46. pmc Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy
    Radha K Shandil
    AstraZeneca India Pvt Ltd, Hebbal, Bellary Road, Bangalore 560024, India
    Antimicrob Agents Chemother 51:576-82. 2007
    ..1 mg/liter (sparfloxacin [SPX]) and 0.5 mg/liter (moxifloxacin [MXF], ciprofloxacin [CIP], and ofloxacin [OFX])...
  47. ncbi Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine
    D Raoult
    Unite des Rickettsies, Faculte de Medecine, Université de la Mediterranée CNRS, Marseille, France
    Arch Intern Med 159:167-73. 1999
    ..Q fever endocarditis, caused by Coxiella burnetii, is fatal in 25% to 60% of patients. Currently, treatment with a long-term tetracycline and quinolone regimen for at least 4 years is recommended, although relapses are frequent...
  48. pmc Intensified treatment with high dose rifampicin and levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial
    Dorothee Heemskerk
    Hospital for Tropical Diseases Oxford University Clinical Research Unit, Wellcome Trust Major Overseas Programme 190 Ben Ham Tu, District 5, Ho Chi Minh City, Vietnam
    Trials 12:25. 2011
    ....
  49. ncbi Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis
    J L Johnson
    Department of Medicine, Division of Infectious Diseases, Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Ohio 44106 5083, USA
    Int J Tuberc Lung Dis 10:605-12. 2006
    ..To evaluate the early bactericidal activity (EBA) of the new fluoroquinolones levofloxacin, gatifloxacin and moxifloxacin in patients with pulmonary tuberculosis (PTB)...
  50. pmc In vitro and in vivo activities of levofloxacin against biofilm-producing Pseudomonas aeruginosa
    H Ishida
    New Product Research Laboratories I, Daiichi Pharmaceutical Co, Ltd, Tokyo, Japan
    Antimicrob Agents Chemother 42:1641-5. 1998
    ..These findings suggest the significant role of levofloxacin in therapy of biofilm bacterium-associated infectious diseases...
  51. ncbi Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy
    Emmanuelle Cambau
    Centre National de Référence pour la Surveillance des Infections à Mycobactéries et de leur Résistance aux Antituberculeux, Laboratoire de Bacteriologie Hygiene, Faculté de Médecine Pitié Salpêtrière, 75634 Paris Cedex 13, France
    Clin Infect Dis 34:39-45. 2002
    ..Molecular detection of ofloxacin resistance (gyrA analysis) was determined for the 12 patients who experienced relapse and who had received ..
  52. ncbi Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong
    Wing Wai Yew
    Tuberculosis and Chest Unit, Grantham Hospital, Hong Kong, China
    Chest 124:1476-81. 2003
    To compare levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis (MDR-TB).
  53. pmc Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis
    Guy E Thwaites
    Centre for Molecular Microbiology and Infection, Imperial College, Exhibition Road, London, United Kingdom
    Antimicrob Agents Chemother 55:3244-53. 2011
    ..Fluoroquinolones add antituberculosis activity to the standard treatment regimen, but to improve outcomes of TBM, they must be started early, before the onset of coma...
  54. pmc In vitro selection of resistance in Escherichia coli and Klebsiella spp. at in vivo fluoroquinolone concentrations
    Lorenzo Drago
    Laboratory of Microbiology, Dept Preclinical Sciences LITA Vialba, University of Milan, Via GB Grassi 74, Milan 20157, Italy
    BMC Microbiol 10:119. 2010
    ..E. coli resistant strains selected after multi-step selection were characterized for DNA mutations by sequencing gyrA, gyrB, parC and parE genes...
  55. pmc Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis
    Charles A Peloquin
    Infectious Disease Pharmacokinetics Laboratory, National Jewish Medical and Research Center, Denver, CO 80206, USA
    Antimicrob Agents Chemother 52:852-7. 2008
    ..All three quinolones showed favorable pharmacokinetic and pharmacodynamic indices, with the most favorable results in this population being seen with levofloxacin at the comparative doses used...
  56. ncbi Comparison of 2 antibiotics that inhibit protein synthesis for the treatment of infection with Yersinia pestis delivered by aerosol in a mouse model of pneumonic plague
    Henry S Heine
    US Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD, 21702, USA
    J Infect Dis 196:782-7. 2007
    ..Intentional release of Yersinia pestis will likely be propagated by aerosol exposure. We explored the effects of neutropenia on the outcome of doxycycline and gentamicin therapy...
  57. ncbi [The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication]
    Ji Hyun Lee
    Department of Internal Medicine, Bundang CHA Hospital, Pochon CHA University College of Medicine, Seongnam, Korea
    Korean J Gastroenterol 48:19-24. 2006
    ..pylori) eradication range from 15 to 20%. This study was aimed to evaluate the efficacy and safety of levofloxacin based triple therapy compared with standard triple or quadruple therapy for H. pylori eradication in Korea...
  58. ncbi In vivo selection during ofloxacin therapy of Escherichia coli with combined topoisomerase mutations that confer high resistance to ofloxacin but susceptibility to nalidixic acid
    Vincent Cattoir
    Service de Bactériologie Virologie Hygiène, AP HP CHU, Henri Mondor Université Paris XII, 51 Avenue du Marechal de Lattre de Tassigny, 94010 Creteil Cedex, France
    J Antimicrob Chemother 58:1054-7. 2006
    To investigate quinolone resistance mechanisms in an Escherichia coli clinical isolate (Ar2) resistant to ofloxacin but susceptible to nalidixic acid selected after 10 days of ofloxacin therapy in a patient with prostatitis.
  59. ncbi Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication
    S Di Caro
    Gastroenterology and Digestive Endoscopy Unit, San Raffaele Giglio Hospital, Cefalù, Italy
    Dig Liver Dis 41:480-5. 2009
    ..Several recent studies suggest levofloxacin-based triple therapies as an alternative rescue treatment. However, dosage and length of levofloxacin-based regimens have not been established...
  60. ncbi Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates
    Zhaogang Sun
    Department of Bacteriology and Immunology, Beijing Tuberculosis and Thoracic Tumor Research Institute, Tongzhou District, Beijing 101149, China
    Int J Antimicrob Agents 31:115-21. 2008
    ..between mutations in the quinolone resistance-determining region (QRDR) of the gyrA gene and drug resistance to ofloxacin, 85 laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis mutant strains and 110 M...
  61. pmc Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin
    Xinying Li
    Public Health Research Institute, 225 Warren St, Newark, NJ 07103, USA
    Antimicrob Agents Chemother 48:4460-2. 2004
    ..Successive mutations raised the mutant selection window. The wild-type selection window for garenoxacin, levofloxacin, and moxifloxacin was also measured...
  62. ncbi Comparative antimicrobial susceptibility of respiratory tract pathogens
    David Felmingham
    G R Micro Ltd, 7 9 William Road, London NW1 3ER, UK
    Chemotherapy 50:3-10. 2004
    ..catarrhalis. However, respiratory fluoroquinolones, of which levofloxacin has been available for the longest time, currently remain active against the great majority of common bacterial respiratory pathogens, including atypicals...
  63. ncbi Ofloxacin population pharmacokinetics in patients with tuberculosis
    J J Stambaugh
    Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado, USA
    Int J Tuberc Lung Dis 6:503-9. 2002
    ..Two tuberculosis hospitals in the United States...
  64. pmc Prevalence and molecular analysis of macrolide and fluoroquinolone resistance among isolates of Streptococcus pneumoniae collected during the 2000-2001 PROTEKT US Study
    Steven D Brown
    Clinical Microbiology Institute, Wilsonville, Oregon, USA
    J Clin Microbiol 42:4980-7. 2004
    ..Almost 90% of the erythromycin-resistant isolates and approximately one-third of the levofloxacin-resistant isolates were multidrug resistant...
  65. ncbi Effect of chitosan on in vitro release and ocular delivery of ofloxacin from erodible inserts based on poly(ethylene oxide)
    G Di Colo
    Department of Bioorganic Chemistry and Biopharmaceutics, University of Pisa, Via Bonanno 33, Italy
    Int J Pharm 248:115-22. 2002
    The effects of chitosan hydrochloride (CH-HCl) on in vitro release of ofloxacin (OFX) from mucoadhesive erodible ocular inserts and on the relevant ocular pharmacokinetics have been studied both to contribute evidence of the ability of ..
  66. ncbi Effects of hepatic fibrosis on ofloxacin pharmacokinetics in rats
    Hui Wang
    Department of Pharmacology, School of Medicine, Wuhan University, Hubei Province, China
    Pharmacol Res 53:28-34. 2006
    The purpose of the present work was to study the pharmacokinetics of ofloxacin, a poorly metabolised drug, in experimental hepatic fibrosis...
  67. ncbi Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial
    S Nouira
    Medical Intensive Care Unit, Fattouma Bourguiba University Hospital, 5000, Monastir, Tunisia
    Lancet 358:2020-5. 2001
    ..Our objective was to assess the effects of ofloxacin in patients with exacerbations of COPD who required mechanical ventilation.
  68. ncbi A clinical trial of pefloxacin and ofloxacin in lepromatous leprosy
    Tranquilino T Fajardo
    Leonard Wood Memorial Center for Leprosy Research, Cebu City 6000, Philippines
    Lepr Rev 75:389-97. 2004
    A 2-month clinical trial of pefloxacin and ofloxacin in previously untreated multibacillary patients was conducted at the Leonard Wood Memorial Leprosy Research Center, Cebu, the Philippines...
  69. ncbi Increasing ofloxacin resistance of bacterial flora from conjunctival sac of preoperative ophthalmic patients in Japan
    Naoyuki Kurokawa
    Department of Ophthalmology, National Tokyo Medical Center, The Policy Based Medical Services Network Study Group for Sensory Organ, Tokyo, Japan
    Jpn J Ophthalmol 46:586-9. 2002
    To examine the in vitro resistance to ofloxacin of preoperative bacterial isolates from the conjunctival sac of Japanese patients.
  70. pmc Quantitative PCR assay to evaluate ampicillin, ofloxacin, and doxycycline for treatment of experimental leptospirosis
    Johann Truccolo
    Leptospira Laboratory, Institut Pasteur de Nouvelle Caledonie, 98845 Nouméa cedex, New Caledonia
    Antimicrob Agents Chemother 46:848-53. 2002
    ..icterohaemorrhagiae strain Verdun to selected antibiotics used in medical practice (ampicillin, doxycycline, and ofloxacin) was evaluated in a Syrian hamster model, to determine the efficacy of these antibiotics during the course of ..
  71. ncbi Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis
    S M Hwang
    Department of Pharmaceutics, College of Pharmacy, Seoul National University, Seoul 151 742, Republic of Korea
    J Control Release 129:100-6. 2008
    Microspheres containing ofloxacin (HMO) with a mean diameter of 2-5 mum were prepared by the co-spray drying of ofloxacin and the sodium salt of hyaluronic acid (hyaluronan)...
  72. ncbi Efficacy of ofloxacin and other ototopical preparations for chronic suppurative otitis media in children
    C D Bluestone
    University of Pittsburgh School of Medicine, and the Department of Pediatrics Otolaryngology, Children s Hospital of Pittsburgh, PA 15213, USA
    Pediatr Infect Dis J 20:111-5; discussion 120-2. 2001
    The safety and efficacy of ototopical preparations, such as ofloxacin, in the treatment of CSOM in infants and children do not currently have approval by the FDA even though ofloxacin is FDA-approved for treatment of CSOM that occurs in ..
  73. pmc Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection
    M K Lacy
    Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City 66160 7231, USA
    Antimicrob Agents Chemother 43:672-7. 1999
    ..Levofloxacin, owing to its larger AUC0-24 values, has excellent and sustained activity against different pneumococcal strains superior to that of ciprofloxacin...
  74. ncbi Activity of ofloxacin against Mycobacterium leprae in the mouse
    J H Grosset
    Département de Bactériologie Virologie, Faculté de Médecine Pitié Salpêtrière, Paris, France
    Int J Lepr Other Mycobact Dis 56:259-64. 1988
    ..leprae in the left hind foot pad were treated from day 62 to day 150 after infection with 50 mg or 150 mg of ofloxacin per kg body weight, 150 mg pefloxacin per kg, or 50 mg prothionamide per kg...
  75. ncbi Intrapulmonary pharmacokinetics of ofloxacin in drug-resistant tuberculosis
    N Chierakul
    Division of Respiratory Disease and Tuberculosis, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Mahidol University, 10700 Bangkok, Thailand
    Int J Tuberc Lung Dis 5:278-82. 2001
    To determine the lung epithelial lining fluid (ELF) and serum levels of ofloxacin in drug-resistant tuberculosis patients during treatment.
  76. ncbi A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin
    M Matsuoka
    Leprosy Research Center, National Institute of Infectious Diseases, 4 2 1 Aobacho, Higashimurayama shi, 189 0002 Tokyo, Japan
    Int J Lepr Other Mycobact Dis 68:452-5. 2000
    ..The isolate was susceptible to clofazimine and clarithromycin, and resistant to dapsone, rifampin, ofloxacin and sparfloxacin. Mutations were identified in the genes associated with resistance to these drugs...
  77. pmc First ruthenium organometallic complex of antibacterial agent ofloxacin. Crystal structure and interactions with DNA
    Iztok Turel
    Faculty of Chemistry and Chemical Technology, University of Ljubljana, Aškerčeva 5, 1000 Ljubljana, Slovenia
    Inorg Chem 49:10750-2. 2010
    An organometallic ruthenium complex of quinolone antibacterial agent ofloxacin, [(η(6)-p-cymene)RuCl(O,O-oflo)]·2.8H(2)O (1·2.8H(2)O), was isolated, and its crystal structure was determined...
  78. ncbi Chitosan microspheres as an alveolar macrophage delivery system of ofloxacin via pulmonary inhalation
    Ju Hwan Park
    National Research Laboratory of Transporters Targeted Drug Design, College of Pharmacy, Seoul National University, Seoul 151 742, Republic of Korea
    Int J Pharm 441:562-9. 2013
    ..survives mainly in the alveolar macrophages, the remedial efficiency of anti-tuberculosis drugs such as ofloxacin may be improved by their direct delivery to the lungs via pulmonary inhalation...
  79. ncbi Oral toxicity of pefloxacin, norfloxacin, ofloxacin and ciprofloxacin: comparison of biomechanical and histopathological effects on Achilles tendon in rats
    Ercan Olcay
    Vatan cad, EmlakBank Evleri, AL, No 4, Faith 34090, Istanbul, Turkey
    J Toxicol Sci 36:339-45. 2011
    Four fluoroquinolones (pefloxacin, norfloxacin, ofloxacin and ciprofloxacin) were compared according to their biomechanical and histopathological effects on rat Achilles tendon...
  80. pmc Rapid detection of isoniazid, rifampin, and ofloxacin resistance in Mycobacterium tuberculosis clinical isolates using high-resolution melting analysis
    Xiaoyou Chen
    Centre for Infectious Diseases and Microbiology Public Health, Institute of Clinical Pathology and Medical Research, Westmead, New South Wales, Australia
    J Clin Microbiol 49:3450-7. 2011
    A high-resolution melting analysis (HRMA) assay was developed to detect isoniazid, rifampin, and ofloxacin resistance in Mycobacterium tuberculosis by targeting resistance-associated mutations in the katG, mabA-inhA promoter, rpoB, and ..
  81. ncbi Synthesis and study of controlled release of ofloxacin from polyester conjugates
    Marcin Sobczak
    Medical University of Warsaw, Faculty of Pharmacy, Department of Inorganic and Analytical Chemistry, ul Banacha 1, 02 097 Warsaw, Poland
    Int J Pharm 402:37-43. 2010
    New polymeric conjugates were prepared coupling ofloxacin to two-, three-, four and six-arm, star-shaped poly(ɛ-caprolactone) and polylactide...
  82. ncbi In vitro availability of ofloxacin in presence of metals essential to human body
    Najma Sultana
    Research Institute of Pharmaceutical Sciences, University of Karachi, Karachi 75270, Pakistan
    Pak J Pharm Sci 20:42-7. 2007
    The significance of interaction between ofloxacin and metals ions was evaluated in this study. The absorption of ofloxacin can be negatively affected by concomitant administration of agents containing metal cations...
  83. ncbi The efficacy of intravitreal levofloxacin and intravitreal dexamethasone in experimental Staphylococcus epidermidis endophthalmitis
    Ozlem Yildirim
    Department of Ophthalmology, Mersin University Faculty of Medicine, Mersin, Turkey
    Ophthalmic Res 34:349-56. 2002
    ..007). Studies on retinal toxicity and dose-response relation are needed to prove the efficacy of levofloxacin in S. epidermidis endophthalmitis...
  84. ncbi Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections
    Mario Furlanut
    Institute of Clinical Pharmacology and Toxicology, Department of Experimental and Clinical Pathology and Medicine, Medical School, University of Udine, Ple S Maria della Misericordia 3, 33100 Udine, Italy
    J Antimicrob Chemother 51:101-6. 2003
    ..The almost complete (> or =99%) absolute oral bioavailability suggests that a comparable exposure to the iv regimen may be achieved after oral administration. The overall clinical success rate was 94.1%...
  85. pmc Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009
    Zhenling Cui
    Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Medical School, Tongji University, Shanghai, China
    BMC Infect Dis 11:78. 2011
    This study aimed to analyze the association of mutation patterns in gyrA and gyrB genes and the ofloxacin resistance levels in clinical Mycobacterium tuberculosis isolates sampled in 2009 from East China.
  86. ncbi Reduction of conjunctival bacterial flora by povidone-iodine, ofloxacin and chlorhexidine in an outpatient setting
    Yaniv Barkana
    Department of Ophthalmology, Assaf Harofe Medical Centre, Beer Yaacov, Zerifin, Israel
    Acta Ophthalmol Scand 83:360-3. 2005
    To compare the reduction of conjunctival bacterial flora by povidone-iodine 4%, ofloxacin 0.3%, and chlorhexidine 0.05% for endophthalmitis prophylaxis before corneal suture removal in an outpatient setting.
  87. ncbi Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose
    Florian M E Wagenlehner
    Department of Urology, St Elisabeth Hospital, St Elisabeth Str 23, D 94315 Straubing, Germany
    Int J Antimicrob Agents 28:551-9. 2006
    ....
  88. ncbi Formulation and in vitro evaluation of ofloxacin-ethocel controlled release matrix tablets prepared by wet granulation method: influence of co-excipients on drug release rates
    Shefaatullah Shah
    Drug Delivery Research Center, Department of Pharmaceutics, Faculty of Pharmacy, Gomal University, Dera Ismail Khan, Pakistan
    Pak J Pharm Sci 24:255-61. 2011
    Being controlled release dosage forms, tablets allow an improved absorption and release profiles of Ofloxacin. The fact that drugs with fine particles size can be compressed well after wetting, so in our research studies Ofloxacin ..
  89. ncbi Prevalence and treatment of Chlamydia trachomatis, Ureaplasma urealyticum, and Mycoplasma hominis in patients with non-gonococcal urethritis
    Dilek Kilic
    Department of Infectious Diseases and Clinical Microbiology, University of Kirikkale Faculty of Medicine, Kirikkale, Turkey
    Jpn J Infect Dis 57:17-20. 2004
    ..In the evaluation of antibiotic susceptibility, higher resistance was obtained against ofloxacin in U. urealyticum, and against erythromycin with M. hominis...
  90. ncbi Formulation, pharmacokinetics and biodistribution of Ofloxacin-loaded albumin microparticles and nanoparticles
    K N Lee
    Poxvirus and Rabies Branch, Centers for Disease Control, 1600 Clifton Rd, Atlanta, GA 30329, USA
    J Microencapsul 28:363-9. 2011
    Albumin microparticles containing Ofloxacin (Fluoroquinolone derivative commonly used in hospitals) were formulated by the spray dry method...
  91. pmc Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from a Korean tertiary care hospital
    Hae Sun Chung
    Department of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, 50 Yonsei ro, Seodaemun gu, Seoul 120 752, Korea
    Yonsei Med J 53:439-41. 2012
    ..Trimethoprim-sulfamethoxazole, minocycline, and levofloxacin were active against most of the isolates tested. Moxifloxacin and tigecycline were also active and hold promise as therapeutic options for S. maltophilia infections...
  92. pmc Effect of N-1/c-8 ring fusion and C-7 ring structure on fluoroquinolone lethality
    Muhammad Malik
    Division of Medicinal and Natural Products Chemistry, University of Iowa, Iowa City, IA 52242, USA
    Antimicrob Agents Chemother 54:5214-21. 2010
    ..Remarkably, structural effects on quinolone lethality were not explained by the recently described X-ray crystal structures of fluoroquinolone-topoisomerase IV-DNA complexes, suggesting the existence of an additional drug-binding state...
  93. ncbi Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin
    Carlos Bergallo
    Hospital Cordoba, Cordoba, Provincia de Cordoba, Argentina, 5000
    Diagn Microbiol Infect Dis 63:52-61. 2009
    ..v. or oral antibiotic treatments, hospital readmissions, or number of patients switched to oral levofloxacin. Tigecycline was safe, effective, and noninferior to levofloxacin in hospitalized patients with CAP...
  94. ncbi Open-label, randomized comparison trial of long-term outcomes of levofloxacin versus standard antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease
    Agustín Ruiz-González
    Department of Medicine, Arnau de Vilanova University Hospital, Lleida, Spain
    Respirology 12:117-21. 2007
    ..This study investigated whether treating acute exacerbations of COPD (AE-COPD) with levofloxacin modifies the long-term outcome of COPD patients in comparison with standard antibiotic regimens...
  95. pmc Vitreous penetration of levofloxacin in the uninflamed phakic human eye
    E N Herbert
    St Paul s Eye Unit, 8Z Link, Royal Liverpool University Hospital, Liverpool L7 8XP, UK
    Br J Ophthalmol 86:387-9. 2002
    ..To assess the vitreous penetration of oral levofloxacin (a new fluoroquinolone antibiotic with improved Gram positive activity) in uninflamed phakic eyes...
  96. ncbi Levofloxacin and rhabdomyolysis in a renal transplant patient
    Asher Korzets
    Department of Nephrology, Hasharon Hospital, Petach Tikva 49372, and Sackler School of Medicine, Tel Aviv University, Israel
    Nephrol Dial Transplant 21:3304-5. 2006
  97. ncbi Comparison of tear sampling techniques for pharmacokinetics analysis: ofloxacin concentrations in rabbit tears after sampling with schirmer tear strips, capillary tubes, or surgical sponges
    D Small
    Department of Pharmacokinetics and Drug Metabolism, Allergan Inc, Irvine, California 92612, USA
    J Ocul Pharmacol Ther 16:439-46. 2000
    ..In vitro, CT, SS, and tear strips were spiked with known volumes of ofloxacin solution in order to assess the bioanalytical accuracy of each technique...
  98. ncbi Bactericidal effect of intravitreal levofloxacin in an experimental model of endophthalmitis
    C Ferrer
    Department of Molecular Biology, VISSUM, Institute of Ophthalmology of Alicante, Alicante, Spain
    Br J Ophthalmol 92:678-82. 2008
    ..To evaluate the efficacy of intravitreal 1.5% levofloxacin versus combined treatment with vancomycin and ceftazidime in an experimental model of bacterial endophthalmitis...
  99. ncbi The role of rpoS gene and quorum-sensing system in ofloxacin tolerance in Pseudomonas aeruginosa
    Shizuo Kayama
    Department of Oral Microbiology, Institute of Health Biosciences, The University of Tokushima Graduate School, Tokushima, Japan
    FEMS Microbiol Lett 298:184-92. 2009
    ..observed to be lower than that of the parental strain in time-dependent killing studies with 8 microg mL(-1) ofloxacin, but the survival rates of the rhlR and rhlI mutants were not different from that of the parental strain...
  100. pmc Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial
    J D C Ross
    Whittall Street Clinic, Whittall Street, Birmingham B4 6DH, UK
    Sex Transm Infect 82:446-51. 2006
    ..prospective, randomised, double blind, parallel group, non-inferiority study compared the efficacy and safety of moxifloxacin monotherapy with ofloxacin plus metronidazole in women with uncomplicated pelvic inflammatory disease.
  101. ncbi Safety of ofloxacin otic and other ototopical treatments in animal models and in humans
    G A Gates
    Department of Otolaryngology-Head and Neck Surgery, University of Washington, Seattle, USA
    Pediatr Infect Dis J 20:104-7; discussion 120-2. 2001
    ..preparations, which caused significant loss of hair cells in the basal turn of the cochlea, ofloxacin caused no loss of hair cells, even at concentrations higher than used clinically...

Research Grants47

  1. Rapid Tests for Drug Resistance to Detect Extensively Drug-Resistant Tuberculosis
    Antonino Catanzaro; Fiscal Year: 2013
    ..e., isoniazid, rifampin, ofloxacin, amikacin, kanamycin, and capreomycin) directly from sputa...
  2. Ocular Drug Delivery Devices for Improved Postoperative Cataract Care
    Buddy D Ratner; Fiscal Year: 2010
    ..The other bead is loaded with an antibiotic (ofloxacin) for the prevention of postsurgical infection...
  3. Aminoglycoside-Enabled Elucidation of Persister Metabolism
    Mark P Brynildsen; Fiscal Year: 2013
    ..to study the metabolic abilities of three persister populations: exponential phase persisters tolerant to ofloxacin, exponential phase persisters tolerant to ampicillin, and stationary persisters tolerant to ofloxacin...
  4. Ocular Disposition of Antimicrobial Agents
    Ashim K Mitra; Fiscal Year: 2010
    ..We also propose to synthesize amino acid, peptide and ascorbate ester prodrugs of erythromycin, levofloxacin and ofloxacin and ascorbate ester prodrugs of ACV, targeted towards the respective transporters expressed on the corneal ..
  5. INNOVATIVE APPROACHES TO TUBERCULOSIS CONTROL
    Richard Chaisson; Fiscal Year: 2009
    ..We will randomize 220 patients to receive moxi alone for 6 months vs. ofloxacin/EMB for 6 months, with outcomes of safety, tolerablility and effectiveness...
  6. Targeted Genetic Modifications of Chlamydia Trachomatis
    ROBERT DE MARS; Fiscal Year: 2004
    ..A cloned mutant gyr A gene that renders Ct resistant to ofloxacin (OFX) will be transferred into sensitive Ct and resistant transformants will be isolated by selection with OFX...
  7. Mechanisms of adverse host responses to antibiotics
    Michael Court; Fiscal Year: 2006
    ..sparfloxacin) compared with 3 fluoroquinolones less commonly associated with these side effects (ciprofloxacin, ofloxacin, and norfloxacin) ...
  8. HAIR ANALYSIS TO MONITOR DRUG ABUSE TREATMENTS
    Diana Wilkins; Fiscal Year: 2001
    ..or methadone), drugs of abuse (morphine, heroin) and marker substances (phenazopyridine or ofloxacin) in hair...
  9. Novel Targets for Treatment of Pseudomonas aeruginosa
    Philip Lister; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  10. Artificial Cornea Based on Photolithographically Patterned, Biomimetic Hydrogels
    Christopher N Ta; Fiscal Year: 2010
    ..3. Determine the skirt design for optimal stromal tissue integration by evaluating in vitro and in vivo stromal wound healing within photolithographically patterned, microperforated hydrogel arrays. ..
  11. Mycoplasma Genitalium and Pelvic Inflammatory Disease
    Catherine Haggerty; Fiscal Year: 2007
    ..Exploring the role of M. genitalium in PID is imperative to optimize diagnosis and treatment and prevent reproductive morbidity among women with nongonococcal/nonchlamydial PID. ..
  12. Infection, Inflammation and Preeclampsia
    Catherine Haggerty; Fiscal Year: 2009
    ..Finally, cytokine and CRP testing may prove to be effective tools for identifying women at risk for developing preeclampsia. ..
  13. Alternative endpoints for plague challenge models
    Richard Frothingham; Fiscal Year: 2005
    ..We will use the data generated to refine our hypotheses and to pursue further funding to complete Aim 3. ..
  14. Strategies to Prevent COPD Exacerbation
    Fernando Martinez; Fiscal Year: 2007
    ..abstract_text> ..
  15. Duke University Center for Translational Research
    Richard Frothingham; Fiscal Year: 2006
    ....
  16. Tinidazole for the Treatment of Bacterial Vaginosis
    Jane Schwebke; Fiscal Year: 2007
    ..In addition, we will measure vaginal and serum concentrations of drug during treatment and correlate with cure rates, short-term recurrence of BV, and severity of infection. ..
  17. Multiplex bead-PCR diagnosis for AIDS diarrhea
    Eric Houpt; Fiscal Year: 2007
    ..Finally, syndrome-based multiplex diagnosis is the platform of the future for clinical microbiology, and if this assay works on stool it should work on sputum, blood, or spinal fluid. [unreadable] [unreadable] [unreadable]..
  18. Topical Antibiotics to Prevent Lyme Disease
    Gary Wormser; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  19. Targeted DNA extraction for Tuberculosis PCR from sputum
    Eric Houpt; Fiscal Year: 2007
    ..The most sensitive procedure will be taken in Phase II and adapted to high-throughput DNA extraction platforms and compared against the standard E- MTD assay. [unreadable] [unreadable] [unreadable]..
  20. Mitochondrial Genomics and Peripheral Neuropathy during HIV Therapy
    Todd Hulgan; Fiscal Year: 2008
    ..Results from this study will also advance the field of "mitochondrial medicine", having broad application across other scientific disciplines and for other human diseases. [unreadable] [unreadable] [unreadable]..
  21. Impact of Medicaid Policy on cardiovascular drug use and clinical outcomes
    Michael A Fischer; Fiscal Year: 2010
    ....
  22. Innate Immunity and exacerbations of COPD
    Sanjay Sethi; Fiscal Year: 2009
    ..The overall goal of this research is to identify specific aspects of the innate defense of the lung that determine the frequency of exacerbations in COPD that will serve as potential therapeutic targets to reduce exacerbations. ..
  23. Mouse Strain dependent innate resistance to intestinal amebiasis
    Eric Houpt; Fiscal Year: 2009
    ....
  24. Hospital-Acquired Infections in the Elderly
    Keith Kaye; Fiscal Year: 2008
    ..The risk factor identified for SSI and MDRB and the impact of SSI and MDRB on health outcomes will be used to design and implement future preventive interventions. ..
  25. Mucosal immune regulation in murine amebic colitis
    Eric Houpt; Fiscal Year: 2007
    ..The comprehensive approach in training and research laid out in this research proposal will guide the applicant towards his goal of being an independent investigator in immunoparasitology. ..
  26. Pain Medication Use & Risk Factors for Opioid Dependence
    Daniel Solomon; Fiscal Year: 2004
    ..Our goal is to use the results of the proposed research to inform a future intervention to improve opioid prescribing within this large pharmacy benefits program. ..
  27. Microporidiosis in AIDS
    ELIZABETH DIDIER; Fiscal Year: 2004
    ..This model will provide a better understanding of how the immune response functions to control microsporidia that replicate in different sites within a host cell. ..
  28. Optimizing dosing to prevent antibiotic resistance
    Martin Evans; Fiscal Year: 2005
    ..We believe understanding the mechanisms underlying resistance will enhance our ability to design alternative dosing strategies to effect clinical cure. ..
  29. Therapy and Prevention for Bacterial Vaginosis
    Jane Schwebke; Fiscal Year: 2006
    ..We will also utilize specimens from these prospective studies to further study the association of Mobiluncus, an organism strongly associated with BV using sensitive PCR technology. ..
  30. Randomized Controlled Testing of Osteoporosis Education
    Daniel Solomon; Fiscal Year: 2006
    ..A multi-disciplinary Training Advisory Board will review the applicants progress regularly to ensure that the proposed training goals are met. ..
  31. Control of Trichomoniasis -A Paradigm for STD Control
    Jane Schwebke; Fiscal Year: 2006
    ..vaginalis, to examine strain differences using PFGE, and to examine the prevalence of resistance strains and their potential contribution to treatment failure. ..
  32. Oxidant Stress and Antioxidants during HIV Therapy
    Todd Hulgan; Fiscal Year: 2007
    ..The candidate's long-term goal is to develop into an independent clinical investigator in this field of study. ..
  33. Real-time PCR diagnostic kit for Giardia and Cryptosporidium
    Eric Houpt; Fiscal Year: 2006
    ..A Phase II application is anticipated to validate the final diagnostic test product against immunoassay for an FDA 501 (k) medical device application. [unreadable] [unreadable] [unreadable]..
  34. Why is Cardiac Risk Increased in Rheumatiod Arthritis
    Daniel Solomon; Fiscal Year: 2002
    ..ability to control for known cardiovascular risk factors, the extensive medication information allowing for us to explore key hypotheses regarding corticosteroid exposure, and the attempt to simultaneously control for disease severity ..
  35. HAEMOPHILUS ANTIGEN REGULATION OF INFLAMMATION IN COPD
    Sanjay Sethi; Fiscal Year: 2003
    ..Identification of the integral bacterial and host components that contribute to immune-mediated inflammation in COPD will ultimately lead to novel therapeutic strategies to alter disease progression and improve outcome in COPD. ..
  36. Minimizing Antibiotic Resistance in Colorado (MARC)
    Ralph Gonzales; Fiscal Year: 2004
    ..pneumoniae infections in and outside the intervention communities. Specific Aim IIIC: Conduct a net-cost analysis of the different levels of community education. ..
  37. Concordance Rates of Mobiluncus Among Sexual Partners
    Jane Schwebke; Fiscal Year: 2004
    ..Our hypothesis is that Mobiluncus curtisii is important in the pathogenesis of BV and high concordance rates among sexual partners will be found suggesting sexual transmission. ..
  38. EVALUATION OF NIKKOMYCIN Z PHARMACOLOGY FOR TREATMENT OF UNCOMPLICATED COCCIDIODE
    David Nix; Fiscal Year: 2009
    ..By carrying out the proposed work, the investigators will resume the clinical development of nikkomycin Z as a potentially curative therapy for coccidioidomycosis so that it may become a candidate for final commercial development. ..
  39. Human Cellular Immune Responses to Leptospira
    Gary Klimpel; Fiscal Year: 2009
    ..Learning how Leptospira interact with the human immune system will lead us to understand the pathogenesis of leptospirosis and how to develop vaccines and strategies to control the associated pathology. ..
  40. IMMUNOLOGY AND MUCOSAL DEFENSE TRAINING PROGRAM
    Gary Klimpel; Fiscal Year: 2004
    ..The Program Director is Peter Ernst, DVM, PhD, Professor of Pediatrics and Senior Scientist, Sealy Center for Molecular Sciences, UTMB. The Co-director is Gary Klimpel. PhD, Professor of Microbiology and Immunology. ..
  41. Improving Antibiotic Use in Acute Care Settings
    Ralph Gonzales; Fiscal Year: 2006
    ..Specific Aim 2: To evaluate the impact of a rapid diagnostic test for c-reactive protein on antibiotic use for adults with acute cough illness when added to a multidimensional intervention. ..
  42. Osteoporosis in Women with Rheumatoid Arthritis
    Daniel Solomon; Fiscal Year: 2006
    ..This epidemiologic data will inform future trials of osteoporosis treatments among patients with RA. As well, the study cohort will comprise one of the largest RA registries with an explicit plan to examine osteoporosis. ..
  43. Tularemia and the Human Innate Immune Response
    Gary Klimpel; Fiscal Year: 2009
    ..abstract_text> ..
  44. BACTERIA INDUCED CYTOKINE PRODUCTION IN THE GUT
    Gary Klimpel; Fiscal Year: 2001
    ....
  45. Damage signaling from irradiated to non-irradiated cells
    EDOUARD AZZAM; Fiscal Year: 2004
    ..They are also relevant to diagnostic and therapeutic nuclear medicine where radionuclides are being investigated to detect various diseases and treat cancer. ..
  46. Optimal Strategies for PID Prevention and Management
    Kenneth Smith; Fiscal Year: 2007
    ..abstract_text> ..